351 related articles for article (PubMed ID: 15191035)
1. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity.
Ponticiello A; Perna F; Maione S; Stradolini M; Testa G; Terrazzano G; Ruggiero G; Malerba M; Sanduzzi A
Respir Med; 2004 Jun; 98(6):509-14. PubMed ID: 15191035
[TBL] [Abstract][Full Text] [Related]
2. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cellular immunity following bacillus Calmette-Guérin therapy in patients with superficial bladder cancer.
Sarica K; Baltaci S; Bedük Y; Süzer O; Kiliç S; Müftüğlu YZ; Göğüş O
Urol Int; 1995; 54(3):137-41. PubMed ID: 7604454
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer.
Patard JJ; Muscatelli-Groux B; Saint F; Popov Z; Maille P; Abbou C; Chopin D
Br J Urol; 1996 Nov; 78(5):709-14. PubMed ID: 8976765
[TBL] [Abstract][Full Text] [Related]
5. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
Ratliff TL; Ritchey JK; Yuan JJ; Andriole GL; Catalona WJ
J Urol; 1993 Sep; 150(3):1018-23. PubMed ID: 8102183
[TBL] [Abstract][Full Text] [Related]
6. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
[TBL] [Abstract][Full Text] [Related]
9. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
13. Influence of intravesical bacillus Calmette-Guérin therapy on systemic immunological status.
Yoshimura K; Yamauchi T
Int J Urol; 1997 Sep; 4(5):456-60. PubMed ID: 9354946
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
[TBL] [Abstract][Full Text] [Related]
15. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
16. Role of the immune response in BCG for bladder cancer.
Ratliff TL
Eur Urol; 1992; 21 Suppl 2():17-21. PubMed ID: 1396942
[TBL] [Abstract][Full Text] [Related]
17. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.
Steg A; Leleu C; Debré B; Boccon-Gibod L; Sicard D
Prog Clin Biol Res; 1989; 310():325-34. PubMed ID: 2672020
[TBL] [Abstract][Full Text] [Related]
18. Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guérin.
Dieli F; Ivanyi J; Marsh P; Williams A; Naylor I; Sireci G; Caccamo N; Di Sano C; Salerno A
J Immunol; 2003 Jan; 170(1):463-9. PubMed ID: 12496432
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin--a useful marker of response?
Schmidt AC; Bouic PJ; Heyns CF; De Kock ML
Br J Urol; 1993 Feb; 71(2):179-82. PubMed ID: 8461951
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]